EMA Recommends Ojemda for Paediatric Low-Grade Glioma

The European Medicines Agency (EMA) has recommended a conditional marketing authorisation for Ojemda (tovorafenib) for the treatment of paediatric low-grade glioma in patients aged 6 months and older who have specific BRAF gene alterations and whose disease has progressed despite prior systemic treatment. This recommendation is based on Phase 2 clinical trial data showing a response rate of 52.6% in 77 patients. Ojemda is a new oral targeted therapy designed to block RAF proteins involved in tumour growth.

This recommendation is a significant step towards early patient access to a new treatment option for a rare paediatric brain tumour. While the conditional authorisation allows for earlier availability, the marketing authorisation holder, Ipsen Pharma, is committed to submitting results from an ongoing Phase 3 study to confirm efficacy and safety. Following the European Commission's decision, individual Member States will determine pricing and reimbursement. Healthcare providers treating paediatric patients with low-grade glioma and drug manufacturers should be aware of this development and its implications for treatment protocols and market access.